Bayer challenges Nexavar generic licence order

In March this year, India had invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation
In his order, Controller of Patents PH Kurian had said the move followed Bayer not doing enough to scale up the sale of the drug despite getting patent for it in India in 2008
http://articles.economictimes.indiatimes.com/2012-05-07/news/31610564_1_drugmaker-bayer-indian-patent-act-cancer-drug